MINNEAPOLIS, Aug. 18,
2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH) today announced that R&D Systems®, a Bio-Techne brand,
has released its new Quantist Luminex® data analysis software.
Compatible with all available Luminex xMAP® instruments, Quantist
software provides fast, reliable analysis of Luminex multiplex
assay data, helping researchers extract valuable insights from
complex data.
The new Quantist software provides researchers with an important
tool for quickly analyzing dozens of analytes with improved
accuracy and efficiency, including the ability to evaluate the
long-term consistency of their Luminex assay data. The intuitive
software interface allows users to easily make inter-assay
comparisons, adjust standard curve parameters, and export optimized
data for creating ready-to-graph Excel files.
"The ability to accurately analyze complex scientific
data and turn it into actionable insights is critical across all
areas of research," said Will Geist,
Bio-Techne's Protein Sciences Segment President. "Quantist helps
meet this fundamental need, allowing researchers to uncover
valuable insights that can accelerate discovery. It also provides
an important component in our ongoing strategy of supporting
customers with end-to-end solutions across their multiplex assay
workflow."
Luminex xMAP technology is a leading bead-based assay platform
that allows for the simultaneous detection of multiple targets in a
single sample. The quantification of multiple cytokines and other
biomarkers in a sample provides critical information about
biological processes and diseases. With Quantist software, R&D
Systems Luminex users now have a comprehensive, end-to-end workflow
solution for intelligent, high-performance multiplexing.
Taken together, R&D Systems® Discovery and High Performance
assays comprise one of the largest, most flexible Luminex analyte
menus available. Assays are available for human, mouse, porcine,
non-human primate, and rat from samples including serum, plasma,
and cell culture media.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH)
is a global life sciences company providing innovative tools and
bioactive reagents for the research and clinical diagnostic
communities. Bio-Techne products assist scientific investigations
into biological processes and the nature and progress of specific
diseases. They aid in drug discovery efforts and provide the means
for accurate clinical tests and diagnoses. With thousands of
products in its portfolio, Bio-Techne generated approximately
$1.1 billion in net sales in fiscal
2022 and has approximately 3,000 employees worldwide. For more
information on Bio-Techne and its brands, please visit
http://www.bio-techne.com
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-release-of-quantist-luminex-data-analysis-software-301607763.html
SOURCE Bio-Techne Corporation